Serum androgens and prostate cancer risk

results from the placebo arm of the Prostate Cancer Prevention Trial

Jeannette M. Schenk, Cathee Till, Ann W. Hsing, Frank Z. Stanczyk, Zhihong Gong, Marian L. Neuhouser, Juergen K. Reichardt, Ashraful M. Hoque, William D. Figg, Phyllis J. Goodman, Catherine M. Tangen, Ian M. Thompson

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can induce prostate cancer (PCA) in laboratory animals, serum-based epidemiologic studies examining androgens in humans have not consistently supported a role for androgens in prostate carcinogenesis. We examined whether pre-diagnostic serum androgens were associated with PCA risk in the placebo arm of the Prostate Cancer Prevention Trial. Methods: In this nested case–control study, cases (n = 1,032) were primarily local-stage, biopsy-detected cancers, and controls (n = 1,025) were biopsy-confirmed to be PCA-free. Pre-diagnostic serum androgens (total testosterone, 3α-androstanediol glucuronide, free testosterone), estrogen-to-testosterone ratio, and sex hormone-binding globulin (SHBG) concentrations were measured in pooled (baseline and year 3) blood samples. Results: We found no significant associations between serum androgens, estrogen-to-testosterone ratios, or SHBG and risk of total, low (Gleason

Original languageEnglish (US)
Pages (from-to)175-182
Number of pages8
JournalCancer Causes and Control
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Androgens
Prostatic Neoplasms
Placebos
Testosterone
Serum
Sex Hormone-Binding Globulin
Prostate
Estrogens
Biopsy
Laboratory Animals
Epidemiologic Studies
Carcinogenesis
Epithelium
Neoplasms

Keywords

  • Androgens
  • Prostate cancer
  • Prostate Cancer Prevention Trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Schenk, J. M., Till, C., Hsing, A. W., Stanczyk, F. Z., Gong, Z., Neuhouser, M. L., ... Thompson, I. M. (2016). Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes and Control, 27(2), 175-182. https://doi.org/10.1007/s10552-015-0695-0

Serum androgens and prostate cancer risk : results from the placebo arm of the Prostate Cancer Prevention Trial. / Schenk, Jeannette M.; Till, Cathee; Hsing, Ann W.; Stanczyk, Frank Z.; Gong, Zhihong; Neuhouser, Marian L.; Reichardt, Juergen K.; Hoque, Ashraful M.; Figg, William D.; Goodman, Phyllis J.; Tangen, Catherine M.; Thompson, Ian M.

In: Cancer Causes and Control, Vol. 27, No. 2, 01.02.2016, p. 175-182.

Research output: Contribution to journalArticle

Schenk, JM, Till, C, Hsing, AW, Stanczyk, FZ, Gong, Z, Neuhouser, ML, Reichardt, JK, Hoque, AM, Figg, WD, Goodman, PJ, Tangen, CM & Thompson, IM 2016, 'Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial', Cancer Causes and Control, vol. 27, no. 2, pp. 175-182. https://doi.org/10.1007/s10552-015-0695-0
Schenk, Jeannette M. ; Till, Cathee ; Hsing, Ann W. ; Stanczyk, Frank Z. ; Gong, Zhihong ; Neuhouser, Marian L. ; Reichardt, Juergen K. ; Hoque, Ashraful M. ; Figg, William D. ; Goodman, Phyllis J. ; Tangen, Catherine M. ; Thompson, Ian M. / Serum androgens and prostate cancer risk : results from the placebo arm of the Prostate Cancer Prevention Trial. In: Cancer Causes and Control. 2016 ; Vol. 27, No. 2. pp. 175-182.
@article{07e836e69d314f75b132b6f284ace18a,
title = "Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial",
abstract = "Background: Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can induce prostate cancer (PCA) in laboratory animals, serum-based epidemiologic studies examining androgens in humans have not consistently supported a role for androgens in prostate carcinogenesis. We examined whether pre-diagnostic serum androgens were associated with PCA risk in the placebo arm of the Prostate Cancer Prevention Trial. Methods: In this nested case–control study, cases (n = 1,032) were primarily local-stage, biopsy-detected cancers, and controls (n = 1,025) were biopsy-confirmed to be PCA-free. Pre-diagnostic serum androgens (total testosterone, 3α-androstanediol glucuronide, free testosterone), estrogen-to-testosterone ratio, and sex hormone-binding globulin (SHBG) concentrations were measured in pooled (baseline and year 3) blood samples. Results: We found no significant associations between serum androgens, estrogen-to-testosterone ratios, or SHBG and risk of total, low (Gleason",
keywords = "Androgens, Prostate cancer, Prostate Cancer Prevention Trial",
author = "Schenk, {Jeannette M.} and Cathee Till and Hsing, {Ann W.} and Stanczyk, {Frank Z.} and Zhihong Gong and Neuhouser, {Marian L.} and Reichardt, {Juergen K.} and Hoque, {Ashraful M.} and Figg, {William D.} and Goodman, {Phyllis J.} and Tangen, {Catherine M.} and Thompson, {Ian M.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s10552-015-0695-0",
language = "English (US)",
volume = "27",
pages = "175--182",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Serum androgens and prostate cancer risk

T2 - results from the placebo arm of the Prostate Cancer Prevention Trial

AU - Schenk, Jeannette M.

AU - Till, Cathee

AU - Hsing, Ann W.

AU - Stanczyk, Frank Z.

AU - Gong, Zhihong

AU - Neuhouser, Marian L.

AU - Reichardt, Juergen K.

AU - Hoque, Ashraful M.

AU - Figg, William D.

AU - Goodman, Phyllis J.

AU - Tangen, Catherine M.

AU - Thompson, Ian M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can induce prostate cancer (PCA) in laboratory animals, serum-based epidemiologic studies examining androgens in humans have not consistently supported a role for androgens in prostate carcinogenesis. We examined whether pre-diagnostic serum androgens were associated with PCA risk in the placebo arm of the Prostate Cancer Prevention Trial. Methods: In this nested case–control study, cases (n = 1,032) were primarily local-stage, biopsy-detected cancers, and controls (n = 1,025) were biopsy-confirmed to be PCA-free. Pre-diagnostic serum androgens (total testosterone, 3α-androstanediol glucuronide, free testosterone), estrogen-to-testosterone ratio, and sex hormone-binding globulin (SHBG) concentrations were measured in pooled (baseline and year 3) blood samples. Results: We found no significant associations between serum androgens, estrogen-to-testosterone ratios, or SHBG and risk of total, low (Gleason

AB - Background: Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can induce prostate cancer (PCA) in laboratory animals, serum-based epidemiologic studies examining androgens in humans have not consistently supported a role for androgens in prostate carcinogenesis. We examined whether pre-diagnostic serum androgens were associated with PCA risk in the placebo arm of the Prostate Cancer Prevention Trial. Methods: In this nested case–control study, cases (n = 1,032) were primarily local-stage, biopsy-detected cancers, and controls (n = 1,025) were biopsy-confirmed to be PCA-free. Pre-diagnostic serum androgens (total testosterone, 3α-androstanediol glucuronide, free testosterone), estrogen-to-testosterone ratio, and sex hormone-binding globulin (SHBG) concentrations were measured in pooled (baseline and year 3) blood samples. Results: We found no significant associations between serum androgens, estrogen-to-testosterone ratios, or SHBG and risk of total, low (Gleason

KW - Androgens

KW - Prostate cancer

KW - Prostate Cancer Prevention Trial

UR - http://www.scopus.com/inward/record.url?scp=84958158968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958158968&partnerID=8YFLogxK

U2 - 10.1007/s10552-015-0695-0

DO - 10.1007/s10552-015-0695-0

M3 - Article

VL - 27

SP - 175

EP - 182

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 2

ER -